Goldman Sachs Group Inc Akero Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 765,741 shares of AKRO stock, worth $41.1 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
765,741
Previous 488,392
56.79%
Holding current value
$41.1 Million
Previous $19.8 Million
106.67%
% of portfolio
0.01%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding AKRO
# of Institutions
298Shares Held
92.4MCall Options Held
1.72MPut Options Held
901K-
Janus Henderson Group PLC London, X06.74MShares$362 Million0.19% of portfolio
-
General Atlantic LLC New York, NY5.73MShares$308 Million10.64% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$300 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$294 Million4.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.53MShares$243 Million0.0% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.49B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...